跳至主要内容
临床试验/JPRN-jRCT2080223520
JPRN-jRCT2080223520已完成3 期

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 3 Study of ITM-058 in Patients with Osteoporosis

Teijin Pharma Limited0 个研究点目标入组 213 人开始时间: 2017年5月8日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
213

研究概览

简要总结

The percent change in lumbar (L1-L4) bone mineral density at the last visit, the abaloparatide group is statistically significant increases to compared to the placebo group in both the entire population of postmenopausal osteoporosis patients and male osteoporosis patients and the subpopulation of postmenopausal osteoporosis patients. There were no clinically relevant findings or new safety concerns regarding safety.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 55age old 至 <= 85age old(—)
性别
All

入选标准

  • Patients with osteoporosis at high risk of fracture

排除标准

  • Patients who may be affected by the secondary osteoporosis
  • Patients who were treated with the drugs that may affect Calcium levels or bone metabolism
  • Patients with a history of osteosarcoma

研究者

相似试验